KRAS and Patent ductus arteriosus: The first study to detect cfDNA in patients with PDA used PCR to amplify the KRAS oncogene in three patients and subsequently used traditional Sanger sequencing to identify mutant variations in the KRAS oncogenes (mut-KRAS) [24].